NovaScan

NovaScan has developed a clinical-stage oncology diagnostic platform for real-time cancer detection and stratification with a low-cost, single-use device. Clinical trials and commercialization efforts are underway for use in lung, breast, skin, GI, and pancreatic cancers, offering the ability to detect malignancy without tissue acquisition. The revolutionary use of the Cole Relaxation Frequency has demonstrated highly accurate results in clinical trials and will provide ex vivo and in vivo detection at the point-of-care, during procedures, and post-procedural pathology. The significant advantages of the platform offer improved patient outcomes, increased physician economies, and reductions in the cost of care

Novascan operates in the Medical equipment manufacturing industry.

Novascan's revenue is 11m - 100m

Novascan has 11 - 50 employees.